Related Experiment Video
Updated: Jan 27, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
[Antihypertensive therapy in chronic kidney disease: what targets and how to reach them]
11 Abteilung Nephrologie, Kantonsspital Aarau.
Insights
Lowering blood pressure in chronic kidney disease (CKD) is key for cardiovascular health. Target systolic office blood pressure is 130-139 mmHg, diastolic 80-89 mmHg, with 24-hour monitoring crucial for CKD patients.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Chronic kidney disease (CKD) patients often exhibit abnormal blood pressure dipping patterns.
- Hypertension is a major risk factor for cardiovascular disease and progression of renal damage in CKD.
- Current guidelines recommend specific blood pressure targets for CKD patients.
Purpose of the Study:
- To define optimal blood pressure targets for lowering cardiovascular risk in CKD.
- To outline strategies for achieving these targets, including medication and lifestyle modifications.
- To emphasize the importance of proteinuria reduction as a secondary treatment goal.
Main Methods:
- Utilizing 24-hour ambulatory blood pressure monitoring to assess dipping status.
- Implementing antihypertensive therapies including diuretics, ACE inhibitors, and ARBs based on proteinuria levels.
- Adjusting diuretic type (thiazide vs. loop) based on estimated glomerular filtration rate (eGFR).
Main Results:
- Recommended systolic office blood pressure: 130-139 mmHg; diastolic: 80-89 mmHg.
- Recommended 24-hour blood pressure: 10 mmHg lower than office readings.
- Proteinuria reduction is crucial for slowing renal function decline, with further BP lowering pursued if tolerated.
- ACE inhibitors/ARBs are indicated for significant proteinuria or microalbuminuria in diabetics.
Conclusions:
- Antihypertensive therapy in CKD requires individualized targets and strategies.
- 24-hour blood pressure monitoring is essential due to altered dipping patterns.
- Combination therapy, often involving at least two drugs, is typically necessary.
- Salt restriction and appropriate diuretic use are fundamental components of management.
Abstract:
Antihypertensive therapy in chronic kidney disease: what targets and how to reach them Abstract. The primary treatment target for lowering cardiovascular risk in chronic renal failure (as well as in the general hypertensive population) is to lower sitting office blood pressure. Since the physiological nocturnal blood pressure drop ("dipping") is frequently absent or even reversed in chronic renal failure (occasionally causing nocturnal blood pressures to be higher than at daytime), 24 hour blood pressure monitoring needs to be liberally used. Systolic office blood pressures should be 130 to 139 mm Hg, diastolic 80 to 89 mm Hg, and 24 hour blood pressures 10 mm Hg lower. In kidney diseases with relevant proteinuria (> 0.5 - 1.0 g / 24 h) and in diabetics with microalbuminuria (> 30 mg / 24 h), proteinuria reduction is an important second treatment goal, because this slows progressive loss of renal function. If there still is relevant proteinuria or (in diabetics, microalbuminuria) after reaching "cardiovascular" blood pressure goals, further lowering of blood pressure below 130 mm Hg systolic should be attempted, if tolerated. Orthostasis, syncope and diastolic blood pressures < 70 mm Hg must by all means be avoided. In addition, there is no demonstrable benefit of lowering systolic blood pressure < 130 mm Hg if eGFR is < 20 ml / min / 1.73 m2. Since intake and excretion of sodium chloride play a central role in the pathogenesis of hypertension in renal failure, habitual salt overconsumers (taking more than approximately 9 g NaCl / 24 h) need to reduce their intake. For the same reason, diuretics are mandatory components of antihypertensive treatment in chronic renal failure, even if there are no signs of volume expansion at all. At eGFRs < 30 ml / min / 1.73 m2, thiazide type diuretics should replaced or supplemented by loop diuretics (e. g. torasemide). SGLT2 inhibitors are adjuvant diuretics in diabetics with an eGFR > 30 ml / min / 1.73 m2. ACE inhibitors or angiotensin 2 receptor antagonists are only mandatory if proteinuria exceeds 0.5 to 1.0 g / 24 h (or in diabetics with microalbuminuria), but not generally in chronic renal failure. At least two antihypertensive drugs are almost always required; at least one should be taken in the evening.
Related Concept Videos
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management
Targeted Cancer Therapies
There are several types of targeted therapies against...
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...

